RETRACTED: Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations (Retracted article. See vol. 24, pg. 1103, 2010)

被引:52
作者
Cilloni, D. [1 ]
Messa, F.
Rosso, V.
Arruga, F.
Defilippi, I.
Carturan, S.
Catalano, R.
Pautasso, M.
Panuzzo, C.
Nicoli, P.
Messa, E.
Morotti, A.
Iacobucci, I. [2 ]
Martinelli, G. [2 ]
Bracco, E.
Saglio, G.
机构
[1] Univ Turin, San Luigi Hosp, Dept Clin & Biol Sci, Div Hematol & Internal Med, I-10043 Turin, Italy
[2] Univ Bologna, Seragnoli Inst, Div Hematol, Dept Hematol & Oncol Sci, Bologna, Italy
关键词
NPM1; NF-kappa B; acute leukemia; chemosensitivity;
D O I
10.1038/leu.2008.68
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Mutations in nucleophosmin (NPM) exon 12 and the resulting delocalization of NPM into the cytoplasm are the most specific and frequent cellular events in acute myeloid leukemia patients (AML) with normal karyotype. Cytoplasmatic NPM (NPMc+) is associated with responsiveness to chemotherapy and better prognosis. The activation of nuclear factor-kappa B (NF-kappa B) has been demonstrated to occur in a subset of AML patients and is thought to induce resistance to many chemotherapeutical agents. In this study, we demonstrate the increased in vitro sensitivity of NPMc+ cells to chemotherapeutical agents and their reduced NF-kappa B activity. Furthermore, we provide evidence of the interaction between NPMc+ and NF-kappa B in the cytoplasm, resulting in the sequestration and inactivation of NF-kappa B. The cytosolic localization and consequent inactivation of NF-kappa B justifies the reduced NF-kappa B DNA-binding activity observed in NPMc+ patients. These data, taken together, may provide a possible explanation for the increased rate of chemosensitivity observed among the NPMc+ patients.
引用
收藏
页码:1234 / 1240
页数:7
相关论文
共 30 条
[1]
Adams J, 1999, CANCER RES, V59, P2615
[2]
Nuclear factor-κ-B:: The enemy within [J].
Aggarwal, BB .
CANCER CELL, 2004, 6 (03) :203-208
[3]
The incidence and clinical significance of nucleophosmin mutations in childhood AML [J].
Brown, Patrick ;
McIntyre, Emily ;
Rau, Rachel ;
Meshinchi, Soheil ;
Lacayo, Norman ;
Dahl, Gary ;
Alonzo, Todd A. ;
Chang, Myron ;
Arceci, Robert J. ;
Small, Donald .
BLOOD, 2007, 110 (03) :979-985
[4]
The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence [J].
Cheng, K. ;
Grisendi, S. ;
Clohessy, J. G. ;
Majid, S. ;
Bernardi, R. ;
Sportoletti, P. ;
Pandolfi, P. P. .
ONCOGENE, 2007, 26 (53) :7391-7400
[5]
The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance [J].
Cilloni, D ;
Messa, F ;
Arruga, F ;
Defilippi, I ;
Morotti, A ;
Messa, E ;
Carturan, S ;
Giugliano, E ;
Pautasso, M ;
Bracco, E ;
Rosso, V ;
Sen, A ;
Martinelli, G ;
Baccarani, M ;
Saglio, G .
LEUKEMIA, 2006, 20 (01) :61-67
[6]
Nuclear factor κB as a target for new drug development in myeloid malignancies [J].
Cilloni, Daniela ;
Martinelli, Giovanni ;
Messa, Francesca ;
Baccarani, Michele ;
Saglio, Giuseppe .
HAEMATOLOGICA, 2007, 92 (09) :1224-1229
[7]
Nucleophosmin is required for DNA integrity and p19Arf protein stability [J].
Colombo, E ;
Bonetti, P ;
Denchi, EL ;
Martinelli, P ;
Zamponi, R ;
Marine, JC ;
Helin, K ;
Falini, B ;
Pelicci, PG .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (20) :8874-8886
[8]
COLOMBO E, CANC RES, V66, P3044
[9]
den Besten W, 2005, CELL CYCLE, V4, P1593
[10]
Identification of nucleophosmin as an NF-κB co-activator for the induction of the human SOD2 gene [J].
Dhar, SK ;
Lynn, BC ;
Daosukho, C ;
St Clair, DK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (27) :28209-28219